Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic and Cardiovascular Disease Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SELENOP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SELENOP Recombinant Protein (Sec-to-Cys Mutants) HEK293 expressed, sequence verified, high purity (>95%), endotoxin controlled (<1.0 EU/μg). Native glycosylation. |
View SELENOP Products |
| Gene Delivery | SELENOP Lentivirus Premade Particles Full-length ORF for stable cell line generation and overexpression validation. |
View SELENOP Products |
| Benchmark Ab | Anti-SELENOP Recombinant Monoclonal Antibody Sequence-verified clinical biosimilar candidate for functional neutralization and positive control. |
View SELENOP Products |
| Validator | SELENOP siRNA Set Target-specific knockdown verification in primary hepatocytes and adipocytes. |
View SELENOP Products |
| Related Target A | LRP8 / ApoER2 Primary endocytic receptor for SELENOP-mediated selenium delivery in the brain and testes. |
View LRP8 Products |
| Related Target B | GPX4 (Glutathione Peroxidase 4) Downstream selenoprotein key to ferroptosis regulation; critical for synergy in metabolic and oncology assays. |
View GPX4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Expression of selenium-rich protein structure | Rational design using Sec-to-Cys (U-to-C) mutations to ensure high-yield, stable recombinant protein expression in HEK293 without losing structural integrity. |
| Receptor binding (LRP8/ApoER2) validation | Purified human and rodent ortholog proteins available with >95% purity for robust ELISA and SPR binding assays. |
| Lack of clinical-grade positive controls | Clinical benchmark recombinant antibodies generated from patent-disclosed sequences for functional neutralization assays. |
| Off-target and specificity validation | Sequence-verified siRNA sets included to confirm target-specific gene knockdown in vitro. |
Live SELENOP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SELENOP therapeutics is intensifying, with major players shifting focus from traditional metabolic profiling to targeted monoclonal antibodies and RNA-based therapies. As first-generation therapies targeting hepatokines reach preclinical and early clinical milestones, the next wave of R&D is targeting the specific blockade of SELENOP-receptor interactions (such as LRP8/ApoER2) to treat Type 2 Diabetes, insulin resistance, non-alcoholic fatty liver disease (NAFLD/NASH), and pulmonary arterial hypertension (PAH).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Solco, Academic Spin-offs | Type 2 Diabetes, NAFLD, PAH | Binding and neutralization assays (Need HEK293-expressed SELENOP and LRP8 proteins) |
| Antisense / siRNA | Alnylam, Ionis | Metabolic Syndrome | In vitro knockdown validation (Need sequence-verified SELENOP siRNA knockdown sets) |
| Small Molecule Inhibitors | Emerging Biotechs | Cardiovascular diseases, Ferroptosis-related pathology | Functional screening (Need stable cell lines generated via Lentivirus Premade Particles) |